| Bioactivity | SBI-183 is an orally active inhibitor of QSOX1 (Kd: 20 μM). SBI-183 suppresses the proliferative and invasive phenotype of renal cancer cell lines, including triple negative breast cancer cell line, lung adenocarcinoma cell line and pancreatic ductal adenocarcinoma. SBI-183 inhibits tumor growth in two human xenograft mouse models of renal cell carcinoma in vivo [1]. |
| Invitro | SBI-183 (6.25-50 μmol/L, 15 min) 以剂量依赖性方式抑制 rQSOX1 的酶活[1]。SBI-183 可抑制肿瘤细胞的增殖，但不会杀死成纤维细胞或快速增殖的 PBMC (0.625-20 μmol/L, 5 days)，抑制786-O、RCJ-41T2 和 MDA-MB-231的活力，IC50 分别为 4.6 μM、3.9 μM 和 2.4 μM (0.076 nM-40 μM, 72 h) [1]。SBI-183 (2.5-20 μM, 4-8 天)对 786-O、RCJ-41T2、MDA-MB-231、A549 和 MIA PaCa2 的二维和三维模型的肿瘤侵袭有剂量依赖性抑制作用[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> SBI-183 相关抗体: Cell Proliferation Assay[1] Cell Line: |
| In Vivo | SBI-183 (786-O: 400 μg/小鼠/天，口服，35 天; RCJ-41T2: 100 mg/kg，口服，21 天) 可分别抑制两种肾细胞癌人异种移植小鼠模型的肿瘤生长[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: |
| CAS | 625403-59-0 |
| Formula | C18H20N2O2 |
| Molar Mass | 296.36 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Fifield, et al. Molecular Inhibitor of QSOX1 Suppresses Tumor Growth In Vivo. Molecular cancer therapeutics. 2020, 19(1), 112–122. |